MedTrace Logo

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

NCT00684918 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2013-08-26

No results posted yet for this study

Summary

This protocol will evaluate the efficacy of obatoclax in older patients with previously untreated AML.

Conditions

Interventions

DRUG

Obatoclax

A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.

Sponsors & Collaborators

  • Gemin X

    lead INDUSTRY

Principal Investigators

  • Jean Viallet, MD · Gemin X Pharmaceuticals

Study Design

Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-08-31
Completion
2009-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00684918 on ClinicalTrials.gov